Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer

Video

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).

With I-SPY2, researchers are able to investigate multiple active agents simultaneously and can minimize the number of patients enrolled to find effective agents, DeMichele explains. In the HER2-positive breast cancer cohort, following the combination treatment, all patients went on to receive 4 cycles of doxorubicin and cyclophasphamide before surgery. The primary endpoint of the trial was pathological complete response (pCR).

Results showed that the combination of T-DM1 and pertuzumab was approximately 30% more likely to achieve a pCR in patients compared with paclitaxel and trastuzumab. Additionally, DeMichele adds, patients in the T-DM1 and pertuzumab arm also experienced less toxicity.

<<<

View more from the 2016 AACR Annual Meeting

Related Videos
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Reshma Lillaney Mahtani, DO
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital